ALS pipeline possesses several potential drugs in mid and late-stage clinical developments to be launched shortly. The major key players in the market includeTofersen/BIIB067 (Biogen/Ionis Pharmaceuticals), Masitinib (AB Science), NurOwn (Brainstorm-Cell Therapeutics), Gold Nanocrystals/CNM-Au8 (Clene Nanomedicine), Verdiperstat (Biohaven Pharmaceuticals), and others.
DelveInsight’s “Amyotrophic Lateral Sclerosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Amyotrophic Lateral Sclerosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Amyotrophic Lateral Sclerosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Amyotrophic Lateral Sclerosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Amyotrophic Lateral Sclerosis: An Overview
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time.
ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by the gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body.
In ALS, both the upper motor neurons and the lower motor neurons degenerate or die and stop sending messages to the muscles. Unable to function, the muscles gradually weaken, start to twitch (called fasciculations), and waste away (atrophy). Eventually, the brain loses its ability to initiate and control voluntary movements. The cause of ALS is not known, and it is not yet known why ALS strikes some people and not others.
However, evidence from scientific studies suggests that both genetics and environment play a role in the development of ALS. Most people with ALS die from respiratory failure, usually within 3–5 years from when the symptoms first appear. However, about 10% of people with ALS survive for 10 or more years.
Amyotrophic Lateral Sclerosis Market Key Facts
-
The United States accounts for the largest market size of ALS compared to EU5 (Germany, the United Kingdom, Italy, France, and Spain) and Japan.
-
In the United States, the market size of ALS is anticipated to rise from USD 324.6 million in 2021 during the forecast period.
-
Among the EU5 countries, Germany had the largest market size (USD 17.7 million) in 2021, while Spain had the smallest with USD 10.7 million.
-
In 2021, Japan accounted for a market size of USD 63.2 million.
-
The total diagnosed prevalent cases of ALS in the 7MM range from 52,099 in 2021 growing at a CAGR of 1.04% during the study period (2019–2032).
-
Among the EU-5 countries in 2021, Germany had the highest diagnosed prevalent cases of ALS with 5,061 cases, followed by the UK (4,276) and Italy (4,226). In contrast, Spain had the lowest cases (3,065) in 2021.
-
Japan accounted for 10,742 diagnosed prevalent ALS cases in 2021.
-
The therapies with the potential to get launched in the forecast period include AMX0035, Tofersen, ION363, NurOwn, Masitinib, Pegcetacoplan (APL-2), and others. The launch of these therapies may increase market size in the coming years, assisted by an increasing patient pool of ALS patients.
Amyotrophic Lateral Sclerosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Amyotrophic Lateral Sclerosis pipeline therapies. It also thoroughly assesses the Amyotrophic Lateral Sclerosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Amyotrophic Lateral Sclerosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Amyotrophic Lateral Sclerosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Amyotrophic Lateral Sclerosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Amyotrophic Lateral Sclerosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Amyotrophic Lateral Sclerosis Epidemiology, Segmented as –
-
Prevalence of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Diagnosed Prevalence Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Gender-Specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Age-specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Type-specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Mutation-Specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Distribution Based on Site of Onset of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
Amyotrophic Lateral Sclerosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Amyotrophic Lateral Sclerosis market or expected to be launched during the study period. The analysis covers the Amyotrophic Lateral Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Amyotrophic Lateral Sclerosis drugs based on their sale and market share.
The report also covers the Amyotrophic Lateral Sclerosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Amyotrophic Lateral Sclerosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Amyotrophic Lateral Sclerosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast
Amyotrophic Lateral Sclerosis Therapeutics Analysis
Currently, the Amyotrophic Lateral Sclerosis Therapeutics market is dominated by the use of Rilutek, Tiglutik, Exservan, Neudexta, Radicava, and others (Anti-epileptic drugs, Opioids, NSAIDs, Diuretics, SSRIs, Antidepressants, etc.)
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Amyotrophic Lateral Sclerosis. Currently, Biogen is leading the therapeutics market with its Amyotrophic Lateral Sclerosis drug candidates in the most advanced stage of clinical development.
Amyotrophic Lateral Sclerosis Companies Actively Working in the Therapeutics Market Include
AB Science, AbbVie, AI Therapeutics, Inc., AL-S Pharma, Alector Inc., Amylyx Pharmaceuticals, Annexon, Inc., Apellis Pharmaceuticals, Inc., Aquestive Therapeutics, Ashvattha Therapeutics, Inc., Avanir Pharmaceuticals (a subsidiary of Otsuka America), Biogen, Biohaven Pharmaceuticals, Brainstorm Cell Therapeutics, Calico Life Sciences LLC, Cellenkos, Clene Nanomedicine Biosciences, Corcept Therapeutics, Covis, Cytokinetics, Cytokinetics/Astellas Pharma, Denali Therapeutics Inc., DS Pharma, Eledon Pharmaceuticals, Ferrer Internacional S.A., Genuv Inc., Helixmith Co., Ltd., InFlectis BioScience, Ionis Pharmaceuticals, Kadimastem, Knopp Biosciences, MediciNova, Mitsubishi Tanabe Pharma Corporation, Molecular Partners, NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Prilenia Therapeutics, Procypra Therapeutics, PTC Therapeutics, QurAlis Corporation, Ra Pharmaceuticals, Rapa Therapeutics LLC, Retrotope, Inc., Revalesio Corporation, Sanofi, PTC Therapeutics, Seelos Therapeutics, UCB Pharma, Woolsey Pharmaceuticals, ZZ Biotech, LLC, and many others.
Emerging and Marketed Amyotrophic Lateral Sclerosis Therapies Covered in the Report Include:
-
AMX0035: Amylyx Pharmaceuticals
-
ANX005: Annexon
-
Exservan: Aquestive Therapeutics
-
ION363: Ionis Pharmaceuticals
-
Masitinib (AB Sciences
-
Nuedexta: Avanir Pharmaceuticals
-
Radicava: Mitsubishi Tanabe Pharma Corporation
-
RNS60: Revalesio Corporation
-
Tiglutik/ Teglutik: ITF Pharma
-
Tofersen: Biogen/Ionis Pharmaceuticals
-
Verdiperstat: Biohaven
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Competitive Intelligence Analysis
4. Amyotrophic Lateral Sclerosis Market Overview at a Glance
5. Amyotrophic Lateral Sclerosis Disease Background and Overview
6. Amyotrophic Lateral Sclerosis Patient Journey
7. Amyotrophic Lateral Sclerosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Amyotrophic Lateral Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Amyotrophic Lateral Sclerosis Unmet Needs
10. Key Endpoints of Amyotrophic Lateral Sclerosis Treatment
11. Amyotrophic Lateral Sclerosis Marketed Therapies
12. Amyotrophic Lateral Sclerosis Emerging Drugs and Latest Therapeutic Advances
13. Amyotrophic Lateral Sclerosis Seven Major Market Analysis
14. Attribute Analysis
15. Amyotrophic Lateral Sclerosis Market Outlook (In US, EU5, and Japan)
16. Amyotrophic Lateral Sclerosis Companies Active in the Market
17. Amyotrophic Lateral Sclerosis Access and Reimbursement Overview
18. KOL Views on the Amyotrophic Lateral Sclerosis Market
19. Amyotrophic Lateral Sclerosis Market Drivers
20. Amyotrophic Lateral Sclerosis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Global Smart Inhalers Market is expected to grow at a CAGR of 21.26% during the forecast period from 2023 to 2028 to 2028. The Smart Inhalers Market is expected to grow owing to the growing prevalence of various respiratory disorders, the rising burden of air pollution across the globe. Moreover, the adoption of digital technology by key pharmaceutical players to provide better solutions for respiratory disorder management as well as increasing awareness related to connective devices in developing nations is also expected to boost the market for smart inhalers.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/